SCT200 Injection in Patients With Head and Neck Squamous Cell Carcinoma
Status:
Unknown status
Trial end date:
2020-05-28
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of first-line with
recombinant anti-EGFR monoclonal antibody（SCT200）and standard chemotherapy in patients with
Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma.